anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This controlled study investigated metabolic changes in non-vaccinated individuals with Long-COVID-19, along with their connection to the severity of the disease. The study involved 88 patients who experienced varying levels of initial disease severity (mild, moderate, and severe), and a control group of 29 healthy individuals. Metabolic risk markers from fasting blood samples were analyzed, and data regarding disease severity indicators were collected. Findings indicated significant metabolic shifts in severe Long-COVID-19 cases, mainly a marked drop in HDL-C levels and a doubled increase in ferritin levels and insulin resistance compared to the mild cases and controls. HDL-C and ferritin were identified as the leading factors predicted by disease severity. In conclusion, the decline in HDL-C levels and rise in ferritin levels seen in Long-COVID-19 individuals, largely influenced by the severity of the initial infection, could potentially play a role in the persistence and progression of Long-COVID-19. Hence, these markers could be considered as possible therapeutic targets, and help shape preventive strategies to reduce the long-term impacts of the disease.
Most critically ill adult patients require ventilatory support during their intensive care unit stay. Following discharge home patients often still suffer from reduced physical function, exercise capacity, health related quality of life and social functioning for at least 2 years. There is usually no support to address these longer term problems specific to critical illness for patients after hospital discharge. Little research has been carried out into interventions which could improve physical function and quality of life, or enhance speed of recovery in these patients. While there is evidence to support the rehabilitation of critically ill patients within intensive care units, there is a paucity of literature to support rehabilitation following discharge from intensive care and hospital. Therefore, there is a clear and urgent need to investigate interventions which could improve the recovery of patients discharged home after intensive care. This is emerging as a prominent therapeutic objective for the future for this population.

This study will investigate whether a programme of exercise following discharge from hospital will improve outcome in patients following critical illness compared to standard care.
Approximately 800 patients will receive either chemotherapy alone or chemotherapy plus Interferon gamma-1b. Chemotherapy will be paclitaxel (175 mg/m2 over 3 hours) followed by carboplatin (AUC 6) every 3 weeks. Only those patients in the treatment arm will receive interferon doses. Interferon gamma-1b 100 mg will be administered subcutaneously 3 times per week (every other day; no more than 3 doses in a 7-day period) continuously while patients are treated with carboplatin / paclitaxel (including for the 3 weeks following the last dose of chemotherapy). A total of 6 cycles of chemotherapy will be given unless disease progression or liming toxicity occurs or patients refuse further treatment. Each patient will receive a total of 54 doses over a period of 18 weeks. Each patient's participation will be from 3-8 years in duration.
OBJECTIVES: The aim was to collect different clinical parameters systematically and proactively regarding safety, effectiveness, and performance of a nylon monofilament suture under routine clinical practice for oral surgery.
METHODS: The study design was prospective, bicentric, international, single-armed, and observational. A non-absorbable suture was applied to close the mucosa after different dental surgical interventions. Main objective was the incidence of combined postoperative complications until suture removal. The 95 % Confidence Interval (Agresti-Coull method) was used to prove the non-inferiority with a pre-specified upper margin of 21.9 %. Secondary variables were intraoperative suture handling, patient pain and satisfaction, wound healing, aesthetic appearance, and bacterial contamination.
RESULTS: 105 patients were enrolled. Complication rate was low (1.9 %), 2 swellings occurred. Pain was present for 1.61 days ± 1.42 after various dental interventions with an average pain level of 20.98 ± 22.60 (VAS). Patients with impacted third molar extraction showed the longest pain duration (6 days) combined with the highest mean pain level of 35.33 ± 30.45 (VAS). Intraoperative suture handling was very good to excellent. Suture removal was done after an average duration of 7.56 ± 2.09 days. Patient's satisfaction was high, and an excellent wound healing was reported by the dentists. Aesthetic appearance only performed in implant patients was rated by oral surgeons with an average of 96.19 ± 3.79 points [min. 80 - max. 100] at 5 months postoperatively. Thread bacterial analysis showed that F. nucleatum was the most present species.
CONCLUSIONS: Our findings indicate that the non-absorbable, nylon-based monofilament suture used is safe and quite suitable for oral mucosal closure after various dental surgical interventions such as tooth extraction, implant placement and impacted third molar extraction.
CLINICAL SIGNIFICANCE: This study showed the safe use of a non-absorbable, nylon-based monofilament suture for different oral surgical interventions under daily routine clinical practice.
FIELD: medicine. SUBSTANCE: the method deals with a preparation for peroral intake of a quick-acting composition to modulate human sexual response and/or treat impotence. Decomposition rate of a quick-acting composition is about 20 min or less. Composition has got an opportunity to deliver a vasodilator into human circulation system. Composition refers to a fast-soluble powder, a press cake, a pellet, suspension and/or solution. Vasodilator is selected out of the group consisted of phentolamine, phenoxybenzamine, nitroglycerin thymoxamine, nicotinylic alcohol, imipramine, verapamyl, isoxuprine, naphthidrofuryl, tolasoline and papaverine or their derivatives. EFFECT: easy-to-use atraumatic preparation with no constant application scheme and multiple doses to meet desired results. 27 cl, 11 tbl, 5 ex
The present application relates to systems and methods for peritoneal dialysis exchange with a reusable energy supply unit. A system and method are provided to allow multiple patients to receive peritoneal dialysis treatment at a walk-in facility without having to keep fresh dialysis solution on their own hands. The walk-in facility enables a peritoneal dialysis prescription to be received from a patient, the prescription to be verified, an appropriate treatment to be used for the patient to be determined, an appropriate amount of an appropriate dialysis solution to be provided to the patient, and a dialysis treatment to be performed by the patient at the facility. The walk-in facility may also enable monitoring of the patient's home dialysis treatment and adjusting the patient's treatment at the facility accordingly. The facility may enable on-demand production of the solution by producing a dialysis solution from solution components according to a patient prescription. In addition, the facility may use a sorbent system to regenerate the effluent dialysis solution into fresh dialysis solution.
Therapeutic bath salts for the relaxation of muscles, elimination or reduction of muscle spasms, and for the overall enhancement of a person's mood. The bath salts of the present invention are used as aromatherapy that has both the convenience of a bath and the internal mechanisms of ingested medication. The formula for the composition of the present invention includes a selected amount of magnesium sulfate trihydrate (a hydrated version of epsom salts), lithium chloride, copper gluconate, and essential oils. The oils include rosewood oil, ylang ylang oil, lavender oil and patchouli oil. The oils are provided as scents for use in the prescribed aromatherapy. The user mixes a preselected amount of the crystallized salt or liquid form of the present invention with the bath water. A period of time is allowed to elapse before the user departs the bath. By resting in the tub, the user accrues the combined benefits of external therapy and internal therapy.
Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to therapy and pulmonology, and can be used for selection of tactics of treating thromboembolism of pulmonary artery. For this purpose computered tomography with bolus enhancement is performed to patient, areas of affection located more distally than thrombotic embolus are examined and number of respiratory movements per minute is taken into account. Presence of occluded vessel or vessels in examined areas is identified. Occlusion of segmental branch of pulmonary artery, located more distally than embolus, is assessed in one point irrespective of degree of vessel occlusion. Occlusion of each of lobar branches in case of affection of right middle lobar, left middle- and upper lobar branches of pulmonary artery is assessed in 2 points. Occlusion of upper lobar branch of pulmonary artery on the right, lower lobar branch of pulmonary artery on the left is assessed in 3 points. Occlusion of right lower lobar branch of pulmonary artery is assessed in 4 points. Occlusion of left main pulmonary artery is assessed in 7 points. Occlusion of right main pulmonary artery is assessed in 9 points. Occlusion of both main pulmonary arteries and/or pulmonary trunk is assessed in 17 points. After that, points are summed up. If the sum of points is from 1 to 6, anticoagulation therapy is performed with heparin. If the sum of points constitutes from 7 to 10 at rate of respiratory movements (RRM) lower than 18, another anticoagulation therapy is performed, at RRM more than 18 - thrombolytic therapy is performed. If the sum of points constitutes from 11 to 17, thrombolytic therapy is performed.EFFECT: method provides possibility of operative objective assessment of degree of pulmonary bed affection and beginning of required therapy in due time.5 dwg, 1 tbl, 4 ex
Malignant melanoma is a neoplasm of melanin-producing cells predominantly of cutaneous origin, which uncommonly develops within gut mucosa. We present the case of a 58-year-old woman with complaints of abdominal pain, loss of appetite and weight. Esophagogastroduodenoscopy revealed a gastric mass and systemic imaging demonstrated widespread nodal and bilateral adrenal gland involvement. Histopathology of the gastric mass confirmed primary malignant mucosal melanoma of the stomach. The patient received three cycles of Nivolumab but did not respond, and thus, was then offered best supportive care. Although infrequent, mucosal melanoma can arise from the gastrointestinal tract, and in contrast to the cutaneous form, advanced disease usually has a dismal prognosis and responds poorly to immune checkpoint inhibitors. Primary gastric melanoma is an aggressive disease that is diagnosed by exclusion after the differential diagnosis of metastasis from a cutaneous or unknown primary site has been conducted. If available, patients with treatment-naïve mucosal melanoma should be considered for enrollment in clinical trials.
Gallbladder cancer (GBC) is a rare but very aggressive most common digestive tract cancer with a high mortality rate due to delayed diagnosis at the advanced stage. Moreover, GBC progression shows asymptomatic characteristics making it impossible to detect at an early stage. In these circumstances, conventional therapy like surgery, chemotherapy, and radiotherapy becomes refractive. However, few studies reported some molecular markers like KRAS (Kirsten Rat Sarcoma) mutation, upregulation of HER2/neu, EGFR (Epidermal Growth Factor Receptor), and microRNAs in GBC. However, the absence of some specific early diagnostic and prognostic markers is the biggest hurdle for the therapy of GBC to date. The present study has been designed to identify some specific molecular markers for precise diagnosis, and prognosis, for successful treatment of the GBC. By In Silico a network-centric analysis of two microarray datasets; (GSE202479) and (GSE13222) from the Gene Expression Omnibus (GEO) database, shows 50 differentially expressed genes (DEGs) associated with GBC. Further network analysis revealed that 12 genes are highly interconnected based on the highest MCODE (Molecular Complex Detection) value, among all three genes; TRIP13 (Thyroid Receptor Interacting Protein), NEK2 (Never in Mitosis gene-A related Kinase 2), and TPX2 (Targeting Protein for Xklp2) having highest network interaction with transcription factors and miRNA suggesting critically associated with GBC. Further survival analysis data corroborate the association of these genes; TRIP13, NEK2, and TPX2 with GBC. Thus, TRIP13, NEK2, and TPX2 genes are significantly correlated with a greater risk of mortality, transforming them from mere biomarkers of the GBC for early detections and may emerge as prognostic markers for treatment.
Participants will receive the following treatment regimens: LDRT cisplatin + etoposide + sugemalimab+olaparib. Induction treatment will be administered on a 21-day cycle for four cycles. LDRT will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase, participants will continue maintenance therapy with sugemalimab and olaparib. Participants will be treated until loss of clinical benefit, or unaccepted toxicity, or withdrawal of consent, or death (whichever occurs first).
Although we demonstrated the overall benefit of fetoscopic laser surgery as first-line treatment in twin-twin transfusion syndrome (TTTS), indications in early stage TTTS are controversial. Indeed, a conservative management with close follow-up is offered in some centers as first-line management for QUINTERO stage 1 TTTS, although this strategy has not been formally compared to first-line fetoscopic placental surgery. The objective of this trial is to compare both strategies for patients with stage 1 TTTS and favorable obstetrical parameters in an international randomized controlled trial. Patients randomized to a conservative management will be followed on a weekly basis as long as the syndrome remains stable using obstetrical and fetal parameters and until an adequate gestational age is reached allowing delivery. Cases progressing to stage ≥ 2 or with a worsening of obstetrical parameters during follow-up in this group will be actively treated by percutaneous laser coagulation. Patients allocated to the "immediate laser" group will be treated by fetoscopic laser surgery within 24 h following randomization. The primary end-point encompasses survival and neurological morbidity at the age of 6 months for each foetus randomized. Analyses and power computations use a cluster-trial methodology that accounts for the inter-twin correlation, with many benefits over more traditional designs using a per-pregnancy outcome. With proportions of 60% and 75% meaning a clinically relevant difference of 15% between the groups, 200 fetuses or equivalently 100 pregnancies would be needed in each arm to reach a power of 80% with an alpha-risk of 5%, allowing 2 interim analyses based upon LAN-DEMETS boundaries and an O'Brien-Fleming function. Inclusion criteria, interventions and randomisation were investigated through a preliminary survey across potential participating centers. Based on this survey, it is anticipated that 3 years will be needed to achieve the requested number of patients. This trial will answer an important question and will help in the management and tailoring of surgical indications in stage 1 TTTS.
Because soft back brace was a custom-made, it began to be worn when enrollment for the study. Brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
Participants in control arm (the conventional nasal cannula group) will receive an oxygen flow of 2-5 L /min. A patient satisfaction survey will be administered after procedure.
The invention discloses a Chinese medicinal preparation for treating rhinitis. The preparation is prepared by the following bulk medicines by weight: 20-30 parts of andrographis paniculata, 20-30 parts of polygonum cuspidatum, 15-25 parts of pogostemon cablin, 15-25 parts of flos magnolia, 10-20 parts of radix scutellariae, 10-20 parts of ephedra, 10-15 parts of angelica dahurica, 5-15 parts of centipeda minima, 5-12 parts of honeysuckle, 3-8 parts of menthol, and 3-8 parts of forsythia. The Chinese medicinal preparation of the invention is mainly used for diminishing inflammation, clearing heat, dispelling wind, dissipating coldness, removing obstruction and reliving pain, and is suitable for chronic simple rhinitis and allergic rhinitis. During treatment, the Chinese medicinal preparation is for oral administration for three times every day, about 3-5g each time. 10 days are taken as a treatment course. Generally, the preparation can take effect in 2 days, and can have an obvious effect in one treatment course. And rhinitis can be cured in 3 treatment courses. Among 279 treated cases, the Chinese medicinal preparation of the invention cures 243 cases, presents substantial effect in 19 cases, takes effect in 15 cases, and has little effect in 2 cases, thus having a total effective rate up to 99.3%.
An apparatus and method that manages preventive-maintenance procedures among users and machines in a cloud network. It employs machine-readable language to: collect written documentation; convert digital audio recordings of crowd-sourced information; parse data; aggregate, normalize, compile and output the data into user-specified reports. Procedures, manuals, equipment maintenance data, and credential data go in; detailed histories of equipment maintenance and user information go out. The apparatus and method facilitates documentation of institutional-equipment-maintenance procedures at various participating locations as the maintenance is performed by a technician. It provides reports about machines in an organization, and groups of machines of identical model numbers among organizations, for use by technicians, managers and manufacturers. It serves to share the workload of managing preventive-maintenance procedures among organizations that use the data, and to provide information lifecycles of equipment.
Some of the clinical features of trigeminal and other facial neuralgias suggest that these painful disorders may be associated with sensitization of central nervous system neurons. Laboratory evidence has shown that central sensitization can be produced and maintained by excitatory amino acids (e.g. glutamate) acting on neurons at NMDA and AMPA/kainate receptor sites. Given this information, and the need for more effective treatments of orofacial neuropathic pain syndromes, two possible candidates worthy of study are 1) dextromethorphan, an NMDA receptor antagonist and 2) topiramate, an anticonvulsant drug with AMPA/kainate receptor blocking activity. Thus, the purpose of this study is to evaluate the efficacy and safety of topiramate (TPM) or high-dose dextromethorphan (DM) versus placebo in the treatment of pain in patients with trigeminal neuralgia (TN) and other orofacial neuropathic pain syndromes. We propose two 6 month studies respectively evaluating dextromethorphan (60 patients; at least 20 with TN, 20 with definite trigeminal nerve pathology and 20 with likely trigeminal nerve pathology) and topiramate (40 patients; at least 20 with TN, 20 with definite trigeminal nerve pathology). These will be double-blind randomized crossover designs comparing high-dose dextromethorphan (DM) versus lorazepam (LOR) (as an active placebo) OR topiramate versus inactive placebo. The primary study outcome measure (in both parts) will be overall daily pain assessed by Gracely pain intensity descriptors. Other recorded data will include adverse drug effects, the frequency, severity and duration of pain paroxysms and a questionnaire focusing on daily function (modification of the Brief Pain Inventory).
A Virtual Reality headset will be used for 30 minutes twice per day outside of usual therapy times while in bed with bedrails raised. Virtual Reality games will be selected that will help with relaxation, pain, and arm and hand recovery after a stroke.
An apparatus comprising a socket insert that is arranged in a receptacle of the apparatus. The socket insert is connected to an operating medium connector. In the receptacle a data interface is covered by the socket insert and inaccessible from outside. To obtain access to the apparatus software or data, the socket insert can be replaced by a service insert that covers the operating medium output but contacts the data plug. The service insert allows communication with the apparatus control to input or output data and/or programs. The arrangement of the service interface covered by socket inserts provides an effective means for access control to the service interface. It impedes or avoids non-authorized access to the interface and damages for persons and material that otherwise could occur due to the missing disruptive discharge proof potential separation between the service interface and particularly the power section of the apparatus control.
Twenty-three participants received five treatment sessions of concurrent sham tDCS and CT on five consecutive days. The current was only delivered in the 30-second ramp-up and 30-second ramp-down periods.
Obesity is a highly prevalent chronic disease that impacts >40% of reproductive-aged females. The pathophysiology of obesity is complex and can be understood simply as a chronic energy imbalance whereby caloric intake exceeds caloric expenditure with an energy surplus stored in adipose tissue. Obesity may be categorized into degrees of severity as well as different phenotypes on the basis of metabolic health and underlying pathophysiology. Obesity and excess adiposity have a significant impact on fertility and reproductive health, with direct effects on the hypothalamic-pituitary-ovarian axis, the ovary and oocyte, and the endometrium. There are significant adverse pregnancy outcomes related to obesity, and excess weight gain before, during, and after pregnancy that can alter the lifelong risk for metabolically unhealthy obesity. Given the high prevalence and pervasive impact of obesity on reproductive health, there is a need for better and individualized care for reproductive-aged females that considers obesity phenotype, underlying pathophysiology, and effective and sustainable interventions to treat obesity and manage weight gain before, during, and after pregnancy.